NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell that is essential for energy metabolism (the electron carrier in the mitochondrial electron transport chain), DNA repair (PARP enzymes consume NAD+ to repair DNA strand breaks), and the activation of sirtuins — NAD+-dependent deacetylases that regulate gene expression, stress response, and longevity pathways. NAD+ levels decline approximately 50% between ages 20 and 50 in human tissue, and this decline is considered by leading longevity researchers to be a significant contributor to the mitochondrial dysfunction, reduced DNA repair capacity, and metabolic deterioration characteristic of aging.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that, in animal studies, dramatically raise tissue NAD+ and produce remarkable anti-aging effects. David Sinclair's 2013 Cell paper demonstrated that NMN restored NAD+ levels and mitochondrial function in aged mice to levels resembling young mice — one of the most cited longevity papers of the decade. The honest evidence summary in humans: NMN raises blood NAD+ levels, improves specific metabolic markers in specific populations, and is safe at studied doses. Whether this translates to meaningful healthspan or lifespan extension in humans remains an open question requiring decades of follow-up data.
| Precursor | Pathway | Human Evidence | Dose | Notes |
|---|---|---|---|---|
| NMN | Direct NAD+ precursor (one step from NAD+); absorbed in small intestine via Slc12a8 transporter | Yoshino 2021 (best trial): +38% muscle NAD+ in prediabetic women; Irie 2020: NMN 250mg safe + raised NAD+ metabolites in healthy men; 7+ completed human trials as of 2026 | 250–500mg/day; sublingual may improve bioavailability vs standard capsule; take with food; timing: morning preferred (NAD+ metabolism has circadian pattern) | Most expensive form; most studied recently; some debate over whether NMN is converted to NR before cell entry (Canto 2015) — if true, NR may be equivalently effective at lower cost |
| NR (Nicotinamide Riboside) | NAD+ precursor (two steps from NAD+ via NMNAT); absorbed and phosphorylated to NMN intracellularly | Trammell 2016 (N=12): NR 1,000mg/day increased blood NAD+ by 2.7×; Elhassan 2019: NR improved muscle mitochondrial function in older adults; more published human trials than NMN as of early 2024 | 500–1,000mg/day; split dosing may be more effective than single dose | Cheaper than NMN; Tru Niagen and Elysium Basis are major commercial products; ChromaDex holds key NR patents; more human trial data than NMN historically though NMN catching up rapidly |
| Niacin (B3) | NAD+ precursor via Preiss-Handler pathway; also raises NAD+ but more indirect; high doses affect lipids | Decades of data; high-dose niacin (1–2g/day) raises HDL dramatically; NAD+-raising at lower doses (50–100mg) well established; HPS2-THRIVE (N=25,673) failed to show CV benefit on statin background — reduced enthusiasm for high-dose niacin | For NAD+ supplementation: 50–100mg niacin (not niacinamide) raises NAD+ at a fraction of NMN/NR cost; high-dose (1g+): causes flushing, liver stress | The cheapest option for NAD+ support; flushing at doses above ~50mg (histamine release in skin); niacinamide (no-flush form) also raises NAD+ but may inhibit sirtuins at high doses (Avalos 2005) |
Who has the most evidence-based rationale for NMN: Adults over 50 with metabolic concerns (prediabetes, insulin resistance, high visceral fat, mitochondrial symptoms like fatigue and reduced aerobic capacity); individuals with low NAD+ related to chronic disease or high PARP demand (active DNA damage, chronic inflammation); those already doing the basics (Zone 2 exercise, adequate sleep, caloric balance) who want to layer in NAD+ support; NOT: healthy young adults in their 20s–30s with no metabolic dysfunction — NAD+ is not significantly depleted and the marginal benefit is likely very small.
Dose and timing: 250–500mg NMN/day is the best-studied range in humans; higher doses (1,000mg+) are taken by many researchers self-experimenting (David Sinclair takes 1g/day publicly) but human RCT data above 500mg is limited; take in the morning — NAD+ metabolism is circadian-regulated, and sirtuins have morning-peak activity; sublingual NMN dissolves under the tongue and may bypass first-pass metabolism for better bioavailability than standard capsules; combine with TMG (trimethylglycine, 500mg) to support methylation if taking high-dose NMN long-term (NMN metabolism may consume methyl groups).
Maximizing NAD+ beyond supplementation: Exercise is the most potent non-supplemental NAD+ raiser — Zone 2 aerobic training activates AMPK → upregulates NAMPT → increases NAD+ biosynthesis; fasting/caloric restriction → AMPK activation → similar effect; these lifestyle interventions raise NAD+ endogenously through increased biosynthesis rather than providing exogenous precursors; they also reduce CD38 expression (by reducing inflammation) — addressing the clearance side of the equation; NMN supplementation + Zone 2 training is a stronger combination than either alone.
Safety: NMN has an excellent short-term safety profile in all completed human trials; no serious adverse events reported at doses up to 1,200mg/day (Liao 2021: N=66, 12 weeks); long-term safety data is still accumulating — the longest completed trials are 12 weeks; theoretical concerns: NMN is a direct NAD+ precursor and NAD+ feeds PARP — PARP inhibitors are used in cancer treatment; whether very high NAD+ could theoretically promote cancer cell proliferation in existing cancer is not definitively answered; no clinical signal of this in healthy populations, but worth noting.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.